CN101011562B - 参芪温胆汤新剂型及其生产方法 - Google Patents
参芪温胆汤新剂型及其生产方法 Download PDFInfo
- Publication number
- CN101011562B CN101011562B CN2006101234030A CN200610123403A CN101011562B CN 101011562 B CN101011562 B CN 101011562B CN 2006101234030 A CN2006101234030 A CN 2006101234030A CN 200610123403 A CN200610123403 A CN 200610123403A CN 101011562 B CN101011562 B CN 101011562B
- Authority
- CN
- China
- Prior art keywords
- shenqi
- decoction
- wendan
- dosage form
- wendan decoction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000010389 wendan Substances 0.000 title claims abstract description 114
- 239000009874 shenqi Substances 0.000 title claims abstract description 109
- 239000002552 dosage form Substances 0.000 title claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 title abstract description 42
- 238000002360 preparation method Methods 0.000 claims abstract description 47
- 241001522129 Pinellia Species 0.000 claims abstract description 27
- 235000006533 astragalus Nutrition 0.000 claims abstract description 27
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 26
- 235000008397 ginger Nutrition 0.000 claims abstract description 26
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 23
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 23
- 244000197580 Poria cocos Species 0.000 claims abstract description 23
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 22
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 22
- 229940010454 licorice Drugs 0.000 claims abstract description 22
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 8
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- 239000000284 extract Substances 0.000 claims description 40
- 239000008187 granular material Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 31
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 22
- 239000002775 capsule Substances 0.000 claims description 20
- 239000006187 pill Substances 0.000 claims description 20
- 239000003826 tablet Substances 0.000 claims description 20
- 239000012141 concentrate Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 241001061264 Astragalus Species 0.000 claims description 17
- 210000004233 talus Anatomy 0.000 claims description 17
- 244000183685 Citrus aurantium Species 0.000 claims description 14
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims description 12
- 235000016646 Citrus taiwanica Nutrition 0.000 claims description 12
- 241000756943 Codonopsis Species 0.000 claims description 12
- 229940032147 starch Drugs 0.000 claims description 12
- 229920001353 Dextrin Polymers 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 11
- 235000019425 dextrin Nutrition 0.000 claims description 11
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 235000013355 food flavoring agent Nutrition 0.000 claims description 10
- 239000011230 binding agent Substances 0.000 claims description 9
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 9
- -1 stir Substances 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 7
- 239000003755 preservative agent Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 238000007689 inspection Methods 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 238000009924 canning Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- KWKVAGQCDSHWFK-VNKDHWASSA-N Methyl sorbate Chemical compound COC(=O)\C=C\C=C\C KWKVAGQCDSHWFK-VNKDHWASSA-N 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- 239000004383 Steviol glycoside Substances 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 229940095672 calcium sulfate Drugs 0.000 claims description 2
- 239000010634 clove oil Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 2
- 239000001375 methyl (2E,4E)-hexa-2,4-dienoate Substances 0.000 claims description 2
- 229910002055 micronized silica Inorganic materials 0.000 claims description 2
- 235000019477 peppermint oil Nutrition 0.000 claims description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 2
- 239000002861 polymer material Substances 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 229960001462 sodium cyclamate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000019411 steviol glycoside Nutrition 0.000 claims description 2
- 229930182488 steviol glycoside Natural products 0.000 claims description 2
- 150000008144 steviol glycosides Chemical class 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 235000008216 herbs Nutrition 0.000 claims 1
- 238000012858 packaging process Methods 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 63
- 239000000463 material Substances 0.000 abstract description 44
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 25
- 208000026435 phlegm Diseases 0.000 abstract description 25
- 208000029078 coronary artery disease Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 238000005516 engineering process Methods 0.000 abstract description 16
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 15
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract description 14
- 230000008901 benefit Effects 0.000 abstract description 11
- 241000045403 Astragalus propinquus Species 0.000 abstract description 10
- 238000009472 formulation Methods 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 238000003860 storage Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 21
- 241000234314 Zingiber Species 0.000 description 19
- 239000000843 powder Substances 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- 241001247821 Ziziphus Species 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 14
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 8
- 235000017491 Bambusa tulda Nutrition 0.000 description 8
- 241001330002 Bambuseae Species 0.000 description 8
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 8
- 239000011425 bamboo Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 206010047700 Vomiting Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- 241000207199 Citrus Species 0.000 description 5
- 206010021143 Hypoxia Diseases 0.000 description 5
- 102000011759 adducin Human genes 0.000 description 5
- 108010076723 adducin Proteins 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 235000020971 citrus fruits Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000007779 soft material Substances 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003908 quality control method Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000007919 dispersible tablet Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000004382 potting Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AXVZFRBSCNEKPQ-UHFFFAOYSA-N N-methyltyramine Chemical compound CNCCC1=CC=C(O)C=C1 AXVZFRBSCNEKPQ-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000012287 Prolapse Diseases 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- BZKUYNBAFQJRDM-UHFFFAOYSA-N aporphine Chemical compound C12=CC=CC=C2CC2N(C)CCC3=CC=CC1=C32 BZKUYNBAFQJRDM-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940109275 cyclamate Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical class C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LPCWDYWZIWDTCV-UHFFFAOYSA-N 1-phenylisoquinoline Chemical compound C1=CC=CC=C1C1=NC=CC2=CC=CC=C12 LPCWDYWZIWDTCV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- KICNEHWPBCQIHQ-UHFFFAOYSA-N 3,6-dimethyl-1-oxa-3,6,8-triazaspiro[4.4]nonane-2,4,7-trione Chemical compound CN1C(=O)OC2(CNC(=O)N2C)C1=O KICNEHWPBCQIHQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000209128 Bambusa Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 235000011297 Brassica napobrassica Nutrition 0.000 description 1
- 241000219192 Brassica napus subsp. rapifera Species 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241001522232 Pinellia ternata Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000068081 Sinocalamus beecheyanus Species 0.000 description 1
- 235000005700 Sinocalamus beecheyanus Nutrition 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- QCMQEZNBBPGFKQ-UHFFFAOYSA-N Thalisopynine Natural products CN1CCC2=C(OC)C(OC)=C(OC)C3=C2C1CC1=C3C=C(OC)C(O)=C1 QCMQEZNBBPGFKQ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000010227 chenpi Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- WQPDQJCBHQPNCZ-UHFFFAOYSA-N cyclohexa-2,4-dien-1-one Chemical compound O=C1CC=CC=C1 WQPDQJCBHQPNCZ-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- FVRABHGHBLRNNR-UHFFFAOYSA-N liriodenine Natural products O=C1C=CC=c2c1cc3nccc4cc5OCOc5c2c34 FVRABHGHBLRNNR-UHFFFAOYSA-N 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药制剂及其生产方法技术领域。参芪温胆汤新剂型是在传统方剂参芪温胆汤汤剂的剂型基础上,应用现代中医药理论和中药制剂生产的新工艺、新技术和新设备,研制开发的一种既能够充分体现中医药特色,又能有效控制产品质量的参芪温胆汤新剂型口服中药制剂。具体地说是采用半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材为主要原料,研制开发的一种具有益气健脾、化湿除痰作用,用于冠心病、心房纤颤等病症的参芪温胆汤新剂型口服中药制剂新产品。参芪温胆汤口服新剂型制剂保持了原有汤剂的固有特色,具有服用剂量少、易服用、剂量准确、质量稳定,适用于商品化大生产。克服了参芪温胆汤汤剂剂型的用量大、携带不方便、不能久贮、无法商品化生产等缺点。
Description
技术领域
本发明属于中药制剂及其生产方法技术领域。
参芪温胆汤新剂型是在传统方剂参芪温胆汤汤剂的剂型基础上,应用现代中医药理论和中药制剂生产的新工艺、新技术和新设备,研制开发的一种既能够充分体现中医药特色,又能有效控制产品质量的中药口服制剂的新剂型。具体地说是采用半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材为主要原料,研制开发的一种具有益气健脾、化湿除痰作用,主要用于冠心病、心房纤颤等病症的参芪温胆汤新剂型中药口服制剂新产品。
背景技术
50多年以来,心血管疾病的发病率和死亡率均高于其它疾病。特别是冠心病,已成为危害人类健康的多发病、常见病。全世界每年有1200万人死于心血管疾病[安尼瓦尔·阿不力孜,冠心病及其危险因素分析,新疆医科大学学报,2005;28(7):688-689]。
冠心病是临床上最常见的心脏病,也是危害人类健康生命的主要心血管病之一,在工业发达国家已成为人口死亡的主要原因,我国冠心病虽属较低发病国家,但目前其发病、死亡率已呈现上升趋势。心血管疾病对健康的严重危害,加之治疗困难和医疗费用昂贵,给个人、家庭和社会带来沉重的经济和精神负担。据全国疾病监测系统资料显示,冠心病死亡率一直呈现上升趋势,1991年死亡率为23.5/10万,到1998年已经上升到42.7/10万,7年间上升了50%左右,采用灰色数列系统模型进行预测,到2010年冠心病死亡率将达到86.9/10万,全国将有120万人死于冠心病。我国冠心病每年新发75万人,心血管病已成为我国城市居民的第一位死因,其死亡率已高于日本、法国、瑞士、比例时等发达地区[陈娜萦,冠心病的发病形势与预防,中华慢病杂志,2005;4(2):41-43]。
中医认为冠心病的发生是由于年老体衰,脏腑功能虚损,阴阳气血失调,加之七情六淫的影响,导致气滞血瘀,胸阳不振,痰浊内生,使心脉痹阻而致病[王炎焱等,冠心病中医研究概况,中医药信息。1999;4:9-10]。
心房纤颤是最常见的持续性心律失常,其患病率在1%左右,且其发病率随年龄增长而逐渐增高。房颤对人群死亡率、致残率的影响非常显著。房颤可引起心悸、头晕、心绞痛甚至心力衰竭等不同的临床症状,且由房颤引起的相关并发症尤其是脑卒中和心力衰竭等对人民群众的生命健康构成了巨大的威胁,同时也消耗了大量的人力物力。房颤已成为21世纪新的心血管流行病。在中国房颤人数接近800万,已成为一个严重威胁人民健康的疾病,我国的房颤患者绝对数量居世界首位,预示了房颤预防和治疗工作的艰巨[孙志军等,心房纤颤的流行病学现状,实用药物与临床,2005;8(4):1-3]。
目前,对于心血管疾病的治疗,主要是纠正易患因素,调整生活方式及西药治疗。药物治疗主要包括硝酸酯类、钙通道阻滞剂及血管紧张素转换酶抑制剂等,这些药物一般起效快,疗效可靠,但反复使用则会产生耐药性或产生不同程度的不良反应。
随着回归自然的呼声日益强烈,中医药中不乏治疗心血管疾病或改善其症状的有效药物和方剂。病机以本虚标实为特点,《素问·至真要大论》云:“太阴在泉……民病积饮,心痛”,《金匮要略心典》亦云:“胸中,心阳……痹阻之处,必有痰浊阻其间”。从临床实际可见,冠心病病人,或形体肥胖,痰湿内蕴;或饱食无度,损伤脾胃,运化失职,水湿停聚为痰,痰为阴邪,其性黏滞,易伤胸阳,致心脉痹阻,不通则痛。因此,对冠心病的治疗必须重视化痰。
参芪温胆汤是由温胆汤加党参和黄芪组成,具有益气健脾、化湿除痰作用,临床应用于治疗冠心病、心房纤颤等疾病,疗效显著。党参、黄芪益气行血,具有扩血管、强心等作用,对心血管疾病有很好的应用价值。温胆汤出自《三因极一病证方论》,由半夏、竹茹、枳实、陈皮、甘草、茯苓、生姜、大枣组成,它能燥湿化痰,降逆除烦,调达气机,使痰湿去,心脉通,则痹痛止,故运用于临床而见良效。现代药理研究表明,温胆汤有扩张冠状动脉,增加冠脉血流量,改善心肌供血的作用,并能降低交感神经兴奋性,增强机体对缺氧的耐受性,以保护对缺氧敏感的心肌,使冠心病的症状得到缓解。另外,温胆汤还有加强心肌收缩,增加心输出量,调节血压,改善微循环的作用[方永奇等,从温胆汤的方证看痰证实质,中国中医基础医学杂志,1998;1(4)1:43-45]。
参芪温胆汤是我国传统的中药复方汤剂,其汤剂剂型的有效成分、药效、质量控制及作用机制等方面还缺乏科学的量化指标,在安全、有效、稳定等方面还缺乏规范化和标准化,难以取得市场的认同。因此,我们应用现代科学方法和先进中药制剂生产技术进行了参芪温胆汤新剂型的现代生产工艺的研究,开发一种既能够体现中医药特色,又能有效控制产品质量的生产工艺方法。
将参芪温胆汤进行剂型改制,研制其口服新剂型是保证产品质量的重要措施。研究参芪温胆汤的有效组分、制备工艺、药效、药理、毒理、剂型等,特别在参芪温胆汤新剂型的提取、分离、纯化、制剂工艺等方面实行标准化,做到定量分析,开发出一种高效、优质、安全、稳定、服用方便的,具有高技术含量、高附加值的新一代参芪温胆汤新剂型的新产品,以满足临床需求,具有重要意义。
参芪温胆汤新剂型口服中药制剂,其产品剂量准确、质量稳定、适用于商品化大生产,克服了参芪温胆汤汤剂剂型的用量大、携带不方便、不能久贮、无法商品化生产等缺点。
发明内容
参芪温胆汤新剂型是在传统方剂参芪温胆汤汤剂剂型的基础上,研制开发的口服制剂新剂型产品。本发明提供了一种具有益气健脾、化湿除痰作用的中药口服制剂新产品的生产工艺方法。
本发明的生产工艺技术,能够充分地提取方剂中的药效物质,保持了原方剂特有的疗效与本质;充分体现了中医治病综合成分作用的特点;用单体成分控制制剂质量,制剂产品具有优良的稳定性,适合于工业化大生产。
1、发明目的
本发明的目的之一,在于提供一种服用方便、疗效确切、质量稳定;具有益气健脾、化湿除痰作用的中药口服制剂新产品,以克服现有产品领域的缺陷,满足临床需要。
本发明的目的之二,在于提供一种采用半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材制备的一种参芪温胆汤新剂型口服制剂的生产工艺方法。将现代科学技术与传统的中药方剂的优势特色相结合,开发生产的技术先进、质量稳定的现代中药制剂新产品、新剂型。
本发明的目的之三,在于提供一种能够保证产品质量、适合于工业化大生产的参芪温胆汤新剂型口服制剂的生产工艺技术条件。对于提高参芪温胆汤新剂型口服制剂产品的质量和实现生产工艺的现代化,具有重要意义。
本发明的目的之四,在于提供一种能够将参芪温胆汤方剂的药效物质最大限度地提取出来,以保持方剂特有的疗效与本质;充分体现中医治病综合成分作用的特点;用单体成分控制制剂质量的参芪温胆汤新剂型口服制剂的生产工艺方法。
2、技术方案
参芪温胆汤是由半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣组成,原剂型为汤剂,存在使用不便、剂量不准、质量不稳定、无法商品化等问题。
参芪温胆汤新剂型是在参芪温胆汤汤剂剂型的基础上,以现代中医药理论和中药制剂生产的新工艺、新技术和新设备为基础,开发研制的一种参芪温胆汤提取物的新剂型产品。具体地说是采用半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材为主要原料,应用现代制药生产工艺技术研制开发的一种具有益气健脾、化湿除痰作用,用于冠心病、心房纤颤等病症的参芪温胆汤新剂型口服制剂新产品。
参芪温胆汤口服液是将药材,经过提取、纯化、浓缩、调剂等工艺制备而成。
参芪温胆汤口服液与传统的汤剂比较,由于去除了部分无效成分及组织物,提高了有效成分的浓度,减少了服用量,而且味道好,易为病人接受。并且,克服了参芪温胆汤汤剂用量大、携带不方便、不能久贮、无法商品化生产等缺点。与相应的固体剂型如片剂、丸剂等比较,因液体制剂分散度大,与机体接触表面增大,故吸收较快,在体内很快达到有效血药浓度,有利于冠心病、心房纤颤等适应症的治疗。其作用通常比较缓和,毒副作用较低,并减少了药物对胃肠道的局部刺激性。
参芪温胆汤颗粒剂、胶囊剂和片剂保持了汤剂作用迅速的特点,且体积小、口感较好,无不良气味,还具有提高生物利用度,提高药物稳定性,携带方便,易于服用、存贮及运输等优点。
参芪温胆汤分散片吸收快,生物利用度高,不良反应小,服用方便,可吞服、咀嚼、含吮,也可置水中分散后单独服用或与果汁、牛奶同服,尤其适合老、幼和吞服固体困难的患者。这对提高疗效,扩大临床应用具有重要意义。
参芪温胆汤丸剂是将处方中药材经提取、粉碎、过筛、灭菌、配料、混合、合坨、制丸、干燥、包装等工序制成。
丸剂制备简便,适用范围广。具有体积小,便于服用,符合中医用药特点,适应机械化生产。不但适于大生产也可小量制备,在众多新剂型不断涌现发展的今天,仍然是临床常用的中药剂型之一。与汤剂相比,丸剂具有药物的有效利用率较高,释药缓慢而持久,适宜于疾病的调养治疗,并能延缓毒剧药物在体内的吸收,减少不良反应,生产设备及技术工艺简单等。
在研制过程中,针对不同的组方、制备工艺找出影响因素,采用正交设计安排实验,确定最佳的组方、提取、精制等工艺条件。体现方剂药效物质提取中,发挥活性混合物综合作用的特点。选择最佳制剂条件,制订质量控制标准,使其稳定性处于最佳状态,提高制剂的质量。采用高效液相色谱法和薄层色谱扫描法等测定有效成分的含量与定性鉴别,是一种定性鉴别专属性强、简便快速,定量分析准确、重现性好、精密度好的产品质量控制方法。本生产工艺简便,生产周期短,有效成分收率高;增加浸出成分的溶解度,产品稳定性好,有广阔的应用前景。
3、优点及效果
本发明的优点之一是:产品服用方便、具有原方原药、疗效确切、产品质量稳定的优点。
参芪温胆汤新剂型口服制剂与汤剂剂型比较,由于去除了无效成分及组织物,提高了有效成分的浓度,减少了服用量,而且口感好,易为病人接受。
本发明的优点之二是:生产工艺适合于工业规模化大生产,产品质量稳定。
本发明的一个重要特点是:在于提供一种能够将方剂的药效物质最大限度地提取出来,保持了原方剂特有的疗效与本质;充分体现了中医治病综合成分作用的特点,并且能够用单体成分控制制剂质量的产品质量控制方法。
参芪温胆汤新剂型保持了原有汤剂的固有特色,而且具有剂量少、易服用、吸收快、疗效好等优点。本发明是以现代中医药理论和中药制剂生产的新工艺、新技术为依托,开发研制的参芪温胆汤新剂型口服制剂。制剂产品具有优良的稳定性,适合工业化生产。
具体实施方式
参芪温胆汤新剂型口服制剂是由半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材提取物与适宜的药用辅料合并制成的。
具体实施是以现代中医药理论为依据,吸取祖国传统医学、现代医学和制药工程技术,并使之有机地结合起来,选取符合《中国药典》2005版一部相关项下要求的半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材,经过提取、精制、灭菌等生产工艺制成的参芪温胆汤新剂型口服制剂新产品。
半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材均是《中国药典》收载的常用重要中药材,矫味剂、药用辅料等均符合《中国药典》和国家的相关法规的相关项下的质量标准。
半夏:为天南星科植物半夏Pinelliaternata(Thunb.)Breit.的干燥块茎,首载于《神农本草经》,已有几千年的用药历史。其性温,味辛,有小毒,归脾、胃、肺经。具有燥湿化痰,降逆止呕,消痞散结之功。用于痰多咳喘,痰饮眩悸,风痰眩晕,痰厥头痛,呕吐反胃,胸脘痞满,梅核气等。半夏含有半夏淀粉75.74%、生物碱、β-谷甾醇、葡萄糖苷、胡萝卜苷、草酸钙、半夏蛋白、氨基酸、脂肪酸、无机元素、半夏胰蛋白酶抑制物、胆碱等。其中,氨基酸计16种,有天门冬氨酸、苏氨酸、丝氨酸、谷氨酸、甘氨酸、丙氨酸、精氨酸、赖氨酸等多种脂肪酸如棕榈酸、硬脂酸、油酸、A-亚麻酸、β-亚麻酸等,无机元素计18种,有Al、Fe、Ca、Mg、K、Na、Ti、Mn、P、Zn等;生物碱类如,左旋盐酸麻黄碱等。半夏临床应用非常广泛,具有十分重要的药用价值。
生姜:是姜科植物姜(Zingiber officinale Rosc.)的新鲜根茎,既是食品,又是临床广泛应用的传统中药。性味辛温,具有散寒解表、温中止吐、回阳通脉、燥湿消痰的功效。可用于风寒表证、咳嗽、肺痿、胃寒呕吐、胸痹和痞证等。民间多用其解鱼蟹毒及生半夏、生南星之毒。生姜主含挥发油和辛辣成份。其芳香和辛辣成份能直接刺激口腔和胃粘膜引起局部血液循环改善,胃液分泌增加,胃酶活性、唾液淀粉酶活性增加,胃肠蠕动增强,有助于提高食欲和促进消化吸收,排出胃肠积气。生姜里含有的辛辣成分被人体吸收后,能抑制体内过氧化脂质的产生,具有抗衰老的功用。
党参:本品为桔梗科植物党参Codonopsis pilosula(Franch.)Nannf.、素花党参Codonopsis piosula Nannf.var.modesta(Nannf.)L.T.Shen或川党参Codonopsis tangshenOliv.的干燥根。味甘、平,归脾、肺经。具有补中益气、健脾益肺的功效,是临床常用的补益中药之一。用于脾肺虚弱,气短心悸,食少便溏,虚喘咳嗽,内热消渴。主要成分为糖类、苷类、黄酮类、三萜类、挥发性成分、生物碱、氨基酸、丰富的微量元素及其他有机成分等。现代药理研究表明,党参具有调节血糖,促进造血机能,降压,抗缺氧,耐疲劳,增强机体免疫力,调节胃收缩及抗溃疡等多种作用。党参对缺血缺氧时细胞能量代谢有明显的改善作用,可明显地提高机体整体的抗缺氧能力,对缺血后自由基的损伤有抑制作用,并有一定的活血化瘀作用。
黄芪:为豆科植物膜荚黄芪(Astragalus membranaceus Bge)和蒙古黄芪(Astragalusmembranaceus Bge.Var.monhokicus(Bge)Hasiao)的干燥根。其味甘、性温,有补气升阳、固表止汗、托毒排脓、利水消肿和生肌等功效,为补气要药。现代研究分析,黄芪含有多种皂甙、黄酮、多糖,以及氨基酸、亚油酸、生物碱、胆碱等复杂的化学成分。药理研究表明,黄芪具有增强肌体的免疫功能,强心、降压、降血糖、利尿、抗衰老、抗肿瘤、抗疲劳、抗病毒、镇静、镇痛等作用。主要用于气虚乏力、食少便溏、中气下陷、久泻脱肛、便血崩漏、表虚自汗、气虚水肿、痈疽难溃、久溃不敛、血虚萎黄、内热消渴等病。黄芪的作用非常广泛,对多种疾病尤其是心血管疾病有很高的应用价值。
竹茹:为禾本科植物青秆竹Bambusa tuldoioles Munro、大头典竹Sinocalamusbeecheyanus(Munro)Mc Clare var.pu bescens P.F.Li或淡竹Phyl21ostachys nigra(lodd)Munro var.henonis Stapf的茎秆的干燥中间层,刮成丝条或削成薄片,性微寒,味甘,归肺胃经。常用于因热痰引起的内、儿、妇各科疾病的治疗。竹茹轻可去实,凉能去热,苦能降下,专清痰,为宁神开郁佳品。是临床不可缺少的常用药。竹茹是中医一味传统的清热化痰药,可除烦止吐、通和脉络。竹茹提取物的主要成分为黄酮糖苷和香豆素内酯,它们是有效的自由基清除剂和天然抗氧化剂。
枳实:为芸香科植物(citrus aurantium L.)酸橙及其栽培变种的干燥未成熟果实或甜橙(C.sinen sisosbeck)的干燥幼果。主要含挥发油、辛弗林、N-甲基酪胺、橙皮甙、维生素C及维生素D等。具有破气消积、化痰散痞的作用。用于积滞内停、痞满胀痛、泻痢后重、大便不通、结胸、胃下垂、脱肛、子宫脱垂等症。临床在胃肠道疾病及心血管疾患方面应用较为广泛。
陈皮:为芸香科植物橘Citrus reticulate Blanco及其栽培变种的干燥成熟果皮。味苦、辛,性温,归肺、脾经。具有理气健脾、燥湿化痰之功效。常用于胸脘胀满、食少吐泻、咳嗽多痰。陈皮含挥发油及橙皮苷等有效成分。
甘草:为豆科植物甘草(Glycyrrhiza uralensis Fisch)、胀果甘草(Glycyrrhiza inflateBat.)或光果甘草(Glycyrrhiza glabra L.)的干燥根和茎,是极为重要的一味中药材。具有补脾益气、清热解毒、缓急止痛之功效。甘草中主要含有甘草酸(glycyrrhizic acid)、甘草次酸、黄酮、生物碱、氨基酸等化学成分,具有广泛的生理活性。甘草酸是其中最为重要的化学成分(其含量最高可达14%),也是研究得最早、最多的化学成分。用于解毒、消炎、抗过敏、抗溃疡、镇咳、抗肿瘤和防治病毒性肝炎、高血脂症和癌症等疾病。
茯苓:为传统的中药材,始载于《神农本草经》,被列为上品。味甘淡,性平,有健脾补中,养心安神,利水渗湿的功能。其药用部位为茯苓菌核,含茯苓多糖约为93%。主要化学成分为:多糖、三萜、脂肪酸、甾醇、酶等。茯苓多糖具有促进细胞分裂、补体激活、抗肿瘤、抗癌等生物活性。主治水湿停滞,小便不利,水肿胀满,食少便溏,心悸失眠。
大枣:为鼠李科植物(Zizp Husjujuba Miil)的成熟果实,大枣作为药用,历史悠久。《伤寒论》、《金匮要略》、《本草纲目》中多有阐述,于《神农本草经》中列为上品,历代本草中均有收载。为补中益气,养血安神,缓和药性的常用中药。大枣含有的酸类有苹果酸、酒石酸、桦木酸等;糖类有多糖及水溶性糖类D-果糖、D-葡萄糖、低聚糖、阿聚糖、半孔荃聚糖、蔗糖等;有机物类有蛋白质、天门冬氨酸、谷氨基酸等多种氨基酸、维生素A、B2、C、P及磷酸腺苷(cAMP);生物碱类有苯基异喹啉型、阿扑啡型、厚阿扑啡型、枣碱及枣宁等;黄酮类化合物有当药黄素(Swertisin)、黄酮-C-葡萄糖苷(Spniosin)、乙酰SpinosinA、B、C等。究最早。大枣具有补血、健脑、抗癌及健脾强身等功效。
本发明的目的是这样实现的:
参芪温胆汤新剂型是由半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材,加水煎煮、合并煎液、浓缩、调剂、干燥等,再加入适宜的药用辅料,制成参芪温胆汤口服液、颗粒剂、胶囊剂、丸剂和片剂。
1、参芪温胆汤口服液及其生产方法:
参芪温胆汤口服液及其生产方法,其特征在于:是由半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味中药材提取物,加入适宜的药用辅料制成参芪温胆汤口服液制剂。
参芪温胆汤口服液及其生产方法,其特征在于:药材的重量百分比含量为:3-11%半夏、3-11%生姜、11-36%党参、11-36%黄芪、3-11%竹茹、3-11%枳实、5-16%陈皮、2-5%甘草、3-9%茯苓和2-5%大枣。
参芪温胆汤口服液及其生产方法,其特征在于:将药材加水煎煮、合并煎液、浓缩等,再与适量的药用辅料混匀,调剂,制成参芪温胆汤口服液制剂的过程。
参芪温胆汤口服液及其生产方法,其特征在于:是由半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味药材提取物、矫味剂、防腐剂和水等组成。
参芪温胆汤口服液及其生产方法,其特征在于:是采用半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味药材提取物,添加矫味剂、防腐剂等,加水调剂;经过罐装、灭菌、检验、包装等生产工艺制备而成。
参芪温胆汤口服液及其生产方法,其特征在于:药材提取液、矫味剂、防腐剂和水的重量百分比含量为药材提取物2-99%、矫味剂0.1-15%、防腐剂0.01-1%和水50-98%,参芪温胆汤口服液每ml液体中相当于含有0.2-9克的生药量。
将参芪温胆汤提取物与适宜的药用辅料制成参芪温胆汤口服液,其特征是药用辅料包括矫味剂、防腐剂;矫味剂是蔗糖、糖精钠、环己基氨基磺酸钠、甜菊糖苷、天门冬酰苯丙氨酸甲酯、乙酰磺胺酸钾、薄荷油(醇)中的一种或二种;防腐剂是丁香油、山梨醇、山梨酸甲酯、苯甲酸类、尼泊金类中的一种。
参芪温胆汤口服液及其生产方法,其特征在于:采取如下步骤的生产工艺:先将药材浸泡,再用水煎煮2-3次;或者,用pH1-2的水作第一煎,pH8-10的水作第二、三煎,煎煮;合并煎液,过滤,除去残渣,滤液减压浓缩;加入乙醇,静置,滤除杂质,回收乙醇,备用;或者,将提取滤液用分离机离心,取上清液,加水调剂,经超滤器超滤,备用;加入矫味剂等,搅拌,混合;加水调剂至制备量;经灭菌、罐装、检验、包装等工艺,即得参芪温胆汤口服液。
2、参芪温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法:
参芪温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法,其特征在于:制备颗粒剂或丸剂或胶囊剂或片剂时,将药材加水煎煮、合并煎液、浓缩、干燥后,与适量的药用辅料混匀,加入粘合剂等制成软材,用制粒机制成颗粒,干燥、整粒,即得颗粒剂;或经过制丸机制成丸剂;或经过硬胶囊填充机制成胶囊剂;或经过压片机制成片剂。
参芪温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法,其特征在于:制备颗粒剂或丸剂或胶囊剂或片剂时,所用的药用辅料,包括稀释剂、粘合剂、润滑剂、表面活性剂;稀释剂包括羧甲基淀粉钠、低取代羟丙基纤维素、交联聚维酮、交联羧甲基纤维素钠、乳糖、硫酸钙、预胶化淀粉、淀粉、糊精、微晶纤维素、硬脂酸钙中的一种或几种;粘合剂包括水、高分子材料、乙醇中的一种或几种;润滑剂包括硬脂酸镁、滑石粉、硬脂酸、微粉硅胶、聚乙二醇-6000中的一种或几种;表面活性剂为十二烷基硫酸钠。
参芪温胆汤颗粒剂、丸剂、胶囊剂和片剂及其生产方法,其特征在于:参芪温胆汤颗粒剂、丸剂、胶囊剂和片剂的每克颗粒中,相当于含有1-15克的生药量。
本发明的参芪温胆汤新剂型产品,按照上述方法制备。用下列实施例进一步阐述,但本发明的保护范围不局限于此。
实施例:
实施例1(参芪温胆汤口服液):
取处方量的半夏12公斤、生姜12公斤、党参40公斤、黄芪40公斤、竹茹12公斤、枳实12公斤、陈皮18公斤、甘草6公斤、茯苓10公斤和大枣6公斤等十味药材,加水浸泡0.5小时;再加水煎煮2次;第1次2.5h,第2次1h;合并煎液,滤过,滤液减压浓缩,加95%乙醇使含醇量达65%,静置48h,回收乙醇,加蒸馏水至总量20L,搅匀,滤过,调pH至6.5,灌封,灭菌,即得。
实施例2(参芪温胆汤口服液):
药材煎煮2次,第1次煎煮1h,第2次煎45min,合并药液,滤过,滤液浓缩至相对密度1.17(80℃),冷却,加入95%乙醇使含醇量为65%静置48h沉淀滤过,滤液回收乙醇并浓缩至相对密度1.20(80℃),加水调剂至1000L,加甜蜜素3kg,苯甲酸钠3kg,搅匀,冷却,过滤,灌封,灭菌即得。
实施例3(参芪温胆汤口服液):
将药材,加水浸渍1h,按煎煮法煎煮2次,第1次2h,第2次1.5h。合并两次煎液,滤过,滤液静置24h;取上清液,浓缩至500L,加入乙醇,使含醇量达60%;静置沉淀,滤过,回收乙醇;滤液调整总量至1000L,加入苯甲酸钠2kg,甜蜜素1kg,混匀,罐封,灭菌,即得。
实施例4(参芪温胆汤口服液):
取处方量的各种药材,加水煎煮2次。第1次2.5h,第2次1h。合并煎液,滤过,滤液减压浓缩,加95%乙醇使含醇量达65%,静置48h,回收乙醇,加蒸馏水至总量1000L,搅匀,冷藏24h,滤过,调pH至6.5,灌封,灭菌,即得。
实施例5(参芪温胆汤口服液):
取处方量的各种药材,第一次煎煮加pH1水煎煮1h,第二次煎煮加pH9水煎煮2h;合并煎液,滤过,滤液减压浓缩至1∶2,加95%乙醇使含醇量达60%,静置48h,回收乙醇,加蒸馏水至总量,搅匀,冷藏24h,滤过,调pH值,灌封,灭菌,即得。
实施例6(参芪温胆汤口服液):
取处方量的各种药材,第一次煎煮加pH2水煎煮1h,第二次煎煮加pH9水煎煮2h;合并煎液,滤过,滤液减压浓缩至1∶1,用管式分离机离心(15000rmin),取上清液,加水调剂,经超滤器超滤,超滤液灌封,灭菌,即得。
实施例7(参芪温胆汤口服液):
先将药材浸泡0.5小时,再用水煎煮3次;用pH2的水作第一煎,pH8的水作第二、三煎,煎煮;合并煎液,过滤,除去残渣;将提取滤液用分离机离心,取上清液,加水调剂,经超滤器超滤,备用;加入矫味剂等,搅拌,混合;加水调剂至制备量;经灭菌、罐装、检验、包装等工艺,即得参芪温胆汤口服液。
实施例8(参芪温胆汤颗粒剂):
参芪温胆汤提取物: 47%
糊精: 47%
微晶纤维素: 2%
甜蜜素: 0.2%
6%聚乙烯吡咯烷酮溶液: 适量
将配方量的药材,煎煮2次,醇沉后常法制得稠浸膏,加入糊精等辅料,制颗粒,干燥整粒,质检,包装于塑料袋中,热熔法封口。
实施例9(参芪温胆汤颗粒剂):
参芪温胆汤提取物 43%
羧甲基淀粉钠 55%
5%PVP作为粘合剂 适量
取处方量的药材,加10倍量水煎煮3h,过滤,滤渣再加8倍量水煎煮2h,过滤,合并煎液,过滤,滤液浓缩至相对密度为1.20-1.25(80℃)的浸膏,再将浸膏减压浓缩,干燥,粉碎,加入羧甲基淀粉钠混匀,以5%PVP作为粘合剂制软材,制粒、干燥、整粒,包装即得。
实施例t0(参芪温胆汤颗粒剂):
将药材加水浸泡半小时,煎煮两次,每次1小时,滤过,合并滤液,浓缩至相对密度1.30左右的浸膏。将浸膏∶糖粉/糊精=1∶3的比例制成软材,用12-16目筛制成颗粒,50--60℃干燥,整粒,即得参芪温胆汤颗粒剂。
实施例11(参芪温胆汤颗粒剂):
喷雾干燥制粒工艺。将已粉碎过120筛的蔗糖和环糊精(配比为2∶1)混合辅料投入流化床制粒中,开动鼓风机,送入热风,进风口温度为80-90℃,出风口温度为50-60℃;使辅料预热10分钟,用0.5%羟丙基甲基纤维素溶液作为黏合剂,开始喷雾制粒。喷雾制粒完成后,继续通热风使颗粒流化干燥15分钟,取样,测水分,使半成品含量在2%以下,停机,出料,整粒,包装即得。
实施例12(参芪温胆汤颗粒剂):
取处方量的半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草和大枣等药材,加10倍量水煎煮3h,过滤,滤渣再加8倍量水煎煮2h,过滤,合并煎液,过滤,滤液浓缩至相对密度为1.20-1.25(80℃)的浸膏,再将浸膏减压浓缩,干燥,粉碎后备用。取处方量的茯苓,粉碎成细粉,过150目筛,备用。将提取物粉、茯苓原粉与辅料混匀,以50%乙醇制软材,制粒、烘干,过筛整粒、分装即得。
实施例13(参芪温胆汤颗粒剂):按重量百分比含量为:
参芪温胆汤提取物 :16-95%
淀粉 :1-45%
糊精 :5-55%
蔗糖 :5-55%
35%乙醇 :适量。
实施例14(参芪温胆汤丸剂)
按处方取原药材,提取,合并药液、过滤、浓缩至稠膏,干燥、打粉,以25%的蜜水作粘合剂,泛制成丸,干燥、包装即得。
实施例15(参芪温胆汤丸剂)
参芪温胆汤提取物干膏粉 :15-95%
淀粉 :5-55%
蜂蜜 :5-25%
糊精 :5-40%
水 :适量。
取提取物干膏粉、糊精和淀粉,混匀,用蜂蜜水制丸,烘干,打光,即得。
实施例16(参芪温胆汤胶囊剂)
配方:半夏6kg、生姜6kg、党参9kg、黄芪9kg、竹茹6kg、枳实6kg、陈皮9kg、甘草3kg、茯苓5kg、大枣3kg。
将茯苓和陈皮75℃烘干,粉成100目药粉,备用;取生姜提取挥发油,用环糊精包合挥发油,备用;将生姜渣与其余药材加10倍量水煎煮三次,每次2hr,过滤,滤液合并,浓缩至1∶1时,加乙醇调整醇浓度为60%,静置24hr,过滤,滤液浓缩至相对密度为1.20-1.35,与上述药粉拌匀,80℃以下干燥,粉碎,加入环糊精包合物混均,装胶囊,包装,灭菌,即得成品。
实施例17(参芪温胆汤胶囊剂)
将茯苓和陈皮烘干,粉成100目药粉,备用;将半夏、生姜、党参、黄芪、竹茹、枳实、甘草和大枣用水煎煮2次,第1次3小时,第2次2小时,合并煎液;减压浓缩至每毫升相当于含有3克生药材的浸膏,加入茯苓和陈皮粉与糊精混合制粒,置烘箱中60℃干燥,用硬胶囊填充机填充胶囊即得。每粒胶囊含生药2g。
实施例18(参芪温胆汤胶囊剂):按重量百分比含量为:
参芪温胆汤提取物 :10-95%
淀粉 :5-55%
硬脂酸镁 :0.001-0.5%
水 :适量。
参芪温胆汤胶囊经提取、浓缩、干燥、粉碎后加入辅料,混均装胶囊,每粒含生药3g。
实施例19(参芪温胆汤片剂):
将半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味药材,水提3次,每次1h,合并煎煮液,过滤;滤液置直空浓缩罐中浓缩至总量的1/3时,500ml/L醇沉12h,60℃以下减压回收乙醇,得浸膏,并继续浓缩至稠膏状,进入烘房80℃烘干,干膏粉碎(过40目筛),得干膏粉;加辅料、制粒、干燥、整粒、压片。
实施例20(参芪温胆汤片剂):
将半夏、生姜、党参、黄芪、竹茹、枳实、陈皮、甘草、茯苓和大枣等十味药材,水提3次,每次1h,合并煎煮液,过滤;浓缩至1∶1,加入95%乙醇,使含醇量达到60%,冷藏12小时,滤过,滤液回收乙醇,浓缩,干燥,得干燥提取物,粉碎(过40目筛),得干膏粉;加辅料、制粒、压片。
实施例21(参芪温胆汤片剂):
参芪温胆汤提取物干膏粉: 35%
糊精: 46.3%
低取代羟丙基纤维素: 8%
5%聚维酮稀醇溶液: 10%
硬脂酸镁: 0.5%
十二烷基硫酸钠: 0.2%
制备工艺:将参芪温胆汤提取物干膏粉,加入配方量的糊精、低取代羟丙基纤维素、置于流化床一步造粒机中,用5%聚维酮的稀醇溶液制粒,再加入配方量的硬脂酸镁和十二烷基硫酸钠,混均,压片即得。
实施例22(参芪温胆汤分散片剂):
参芪温胆汤提取物干膏粉(粉碎过200目筛): 81.3%
低取代羟丙基纤维素: 5%
羟丙基甲基纤维素的稀醇溶液: 12%
微粉硅胶: 1.5%
十二烷基硫酸钠: 0.2%
制备工艺:将参芪温胆汤提取物干膏粉(粉碎过200目筛),加入配方量60%的低取代羟丙基纤维素、置于流化床一步造粒或真空造粒机中,用0.5%羟丙基甲基纤维素的稀醇溶液制粒,再加入配方量的40%低取代羟丙基纤维素、微粉硅胶和十二烷基硫酸钠,混均,压片即得。
实施例23(参芪温胆汤分散片剂):
参芪温胆汤提取物干膏粉: 55%
低取代羟丙纤维素: 8%
微晶纤维素: 5%
预胶化淀粉: 30%
微粉硅胶: 0.5%
硬脂酸镁: 0.3%
淀粉浆: 适量
制备工艺:按处方量称取参芪温胆汤提取物干膏粉、低取代羟丙纤维素、微晶纤维素、预胶化淀粉等,淀粉浆作为粘合剂,其余原料过80目筛,加淀粉浆制软材后,过40目筛制粒,50℃烘干,40目整粒,加入0.5%微粉硅胶、0.3%硬脂酸镁,混合均匀,压片。
Claims (4)
1.一种参芪温胆汤口服制剂新剂型,其特征在于:以原料药材总量的重量百分比计,3-11%半夏、3-11%生姜、11-36%党参、11-36%黄芪、3-11%竹茹、3-11%枳实、5-16%陈皮、2-5%甘草、3-9%茯苓和2-5%大枣,按下述方法制成:先将药材浸泡,用水煎煮2-3次,或者用pH1-2的水作第一煎,pH8-10的水作第二、三煎,煎煮,合并煎液,过滤,除去残渣;滤液减压浓缩,加入乙醇,静置,滤除杂质,回收乙醇,或者提取滤液用分离机离心;取上清液,加水调剂,经超滤器超滤,加入矫味剂,搅拌,混合,加水调剂至制备量经灭菌、罐装、检验、包装工艺,即得一种参芪温胆汤口服制剂新剂型。
2.根据权利要求1所述的一种参芪温胆汤口服制剂新剂型,其特征在于:所述的参芪温胆汤新剂型口服制剂是指参芪温胆汤口服液、颗粒剂、胶囊剂、丸剂或片剂。
3.根据权利要求2所述的一种参芪温胆汤口服制剂新剂型,其特征在于:将参芪温胆汤提取物与适宜的药用辅料制成参芪温胆汤口服液时,其药用辅料包括矫味剂、防腐剂;矫味剂是蔗糖、糖精钠、环己基氨基磺酸钠、甜菊糖苷、天门冬酰苯丙氨酸甲酯、乙酰磺胺酸钾、薄荷油中的一种或二种;防腐剂是丁香油、山梨醇、山梨酸甲酯、苯甲酸类、尼泊金类中的一种。
4.根据权利要求2所述的一种参芪温胆汤口服制剂新剂型,其特征在于:制备参芪温胆汤颗粒剂或丸剂或胶囊剂或片剂时,所用的药用辅料,包括稀释剂、粘合剂、润滑剂、表面活性剂;稀释剂包括羧甲基淀粉钠、低取代羟丙基纤维素、交联聚维酮、交联羧甲基纤维素钠、乳糖、硫酸钙、预胶化淀粉、淀粉、糊精、微晶纤维素、硬脂酸钙中的一种或几种;粘合剂包括水、高分子材料、乙醇中的一种或几种;润滑剂包括硬脂酸镁、滑石粉、硬脂酸、微粉硅胶、聚乙二醇-6000中的一种或几种;表面活性剂为十二烷基硫酸钠。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101234030A CN101011562B (zh) | 2006-11-09 | 2006-11-09 | 参芪温胆汤新剂型及其生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101234030A CN101011562B (zh) | 2006-11-09 | 2006-11-09 | 参芪温胆汤新剂型及其生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101011562A CN101011562A (zh) | 2007-08-08 |
CN101011562B true CN101011562B (zh) | 2010-04-07 |
Family
ID=38699402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101234030A Expired - Fee Related CN101011562B (zh) | 2006-11-09 | 2006-11-09 | 参芪温胆汤新剂型及其生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101011562B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688356B (zh) * | 2012-06-19 | 2014-03-12 | 黄芸 | 缓解气虚型冠心病中药口服液及制备方法 |
PL3317260T3 (pl) | 2016-09-21 | 2020-05-18 | Celanese International Corporation | Kompozycje acesulfamu potasu oraz sposoby jego wytwarzania |
WO2018057388A1 (en) | 2016-09-21 | 2018-03-29 | Celanese International Corporation | Acesulfame potassium compositions and processes for producing same |
HUE051522T2 (hu) | 2016-09-21 | 2021-03-01 | Celanese Int Corp | Aceszulfám-kálium készítmények és eljárások elõállításukra |
PT3319948T (pt) | 2016-09-21 | 2021-09-13 | Celanese Int Corp | Composições de acessulfame de potássio e processos para produzir as mesmas |
CN114426913A (zh) * | 2020-10-29 | 2022-05-03 | 程枫 | 一种抗风湿疼痛的保健酒 |
CN117653698B (zh) * | 2022-08-29 | 2025-05-27 | 上海中医药大学附属龙华医院 | 一种治疗心房颤动的中药组合物 |
-
2006
- 2006-11-09 CN CN2006101234030A patent/CN101011562B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
陈火花.温胆汤的衍变及其临床应用.中医药研究2 18.2002,2(18),17-18. * |
Also Published As
Publication number | Publication date |
---|---|
CN101011562A (zh) | 2007-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101011562B (zh) | 参芪温胆汤新剂型及其生产方法 | |
CN104288501A (zh) | 一种降糖颗粒及其制备方法 | |
CN101011561A (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
CN107616501A (zh) | 一种具有清肺功能的组合物及其制备方法 | |
JP2002154979A (ja) | I型アレルギー用医薬組成物およびその製造方法 | |
CN108210547B (zh) | 一种余甘子叶提取物的制备方法及其制剂与抗艾应用 | |
CN114404517A (zh) | 一种用于痛风和降低尿酸的组合物及其用途与制备方法 | |
CN101172155A (zh) | 生脉温胆汤新剂型及其生产方法 | |
CN104173585A (zh) | 一种含红景天的适应原制剂及其制备方法 | |
CN105582124B (zh) | 一种治疗便秘的中药及其制备方法 | |
CN101390970B (zh) | 一种治疗乙肝的中药及其制备方法 | |
CN103705578B (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
CN110876772A (zh) | 一种具有保肝护肝功能的中药制剂的制备方法及应用 | |
CN101919919B (zh) | 腹可安分散片及其制备方法 | |
CN114748440A (zh) | 芪胶升白胶囊组合物及其制法和用途 | |
CN105663439A (zh) | 一种用于预防和治疗糖尿病的药物组合物及其制备方法 | |
CN108210651B (zh) | 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法 | |
CN113456776A (zh) | 增强免疫力预防老年性痴呆调节血糖血脂血压的组合物 | |
CN1723986A (zh) | 贞芪扶正泡腾片及其制备工艺 | |
CN110664905A (zh) | 一种用于祛风散寒的中药制剂及其制备方法 | |
CN105169187B (zh) | 一种组合物及其应用,其制备方法以及含有该组合物的药物、食品 | |
CN1248463A (zh) | 仙草养颜膏及其制备工艺 | |
CN103705831B (zh) | 一种治疗绝经前后诸证的药物组合物及其制备方法 | |
CN101264172A (zh) | 一种戒毒中药组合物的制备方法和其应用 | |
CN101028392B (zh) | 一种治疗高脂血症的中成药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Zhanfei Document name: Notification to Pay the Fees |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100407 |